A detailed history of Nordea Investment Management Ab transactions in Arvinas, Inc. stock. As of the latest transaction made, Nordea Investment Management Ab holds 223,690 shares of ARVN stock, worth $4.27 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
223,690
Previous 236,174 5.29%
Holding current value
$4.27 Million
Previous $6.29 Million 12.36%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$23.66 - $32.73 $295,371 - $408,601
-12,484 Reduced 5.29%
223,690 $5.51 Million
Q2 2024

Aug 08, 2024

SELL
$24.46 - $40.4 $985,933 - $1.63 Million
-40,308 Reduced 14.58%
236,174 $6.29 Million
Q1 2024

May 02, 2024

SELL
$36.38 - $52.31 $82,036 - $117,959
-2,255 Reduced 0.81%
276,482 $11.4 Million
Q4 2023

Jan 10, 2024

SELL
$14.19 - $42.33 $89,638 - $267,398
-6,317 Reduced 2.22%
278,737 $11.5 Million
Q3 2023

Nov 13, 2023

SELL
$19.64 - $28.21 $123,869 - $177,920
-6,307 Reduced 2.16%
285,054 $5.6 Million
Q2 2023

Jul 07, 2023

SELL
$21.73 - $31.43 $406,981 - $588,652
-18,729 Reduced 6.04%
291,361 $7.23 Million
Q1 2023

Apr 19, 2023

BUY
$26.15 - $37.26 $944,930 - $1.35 Million
36,135 Added 13.19%
310,090 $8.47 Million
Q4 2022

Feb 08, 2023

BUY
$32.47 - $57.24 $7.92 Million - $14 Million
244,065 Added 816.54%
273,955 $9.37 Million
Q3 2022

Oct 19, 2022

BUY
$41.87 - $57.99 $878,013 - $1.22 Million
20,970 Added 235.09%
29,890 $1.36 Million
Q2 2022

Aug 09, 2022

BUY
$36.01 - $74.24 $184,983 - $381,370
5,137 Added 135.79%
8,920 $373,000
Q1 2022

Apr 11, 2022

BUY
$60.27 - $81.57 $228,001 - $308,579
3,783 New
3,783 $245,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Nordea Investment Management Ab Portfolio

Follow Nordea Investment Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Nordea Investment Management Ab with notifications on news.